IDH1‐mutated AMLRelapsed/refractory cohort:Aged ≥18 y (23% ≥75 y)Cytogenetics: intermediate (59%) or poor risk (28%), missing (13%)ECOG PS ≤2Secondary AML (33%)Newly diagnosed cohort:Aged ≥75 y (32% <75 y)ECOG PS ≤2Severe cardiac or pulmonary diseaseHepatic impairment (bilirubin >1.5 × ULN)Creatinine clearance <45 mL/minCytogenetics: intermediate (32%) or poor risk (68%)Therapy‐related AML (11%). This evidence concerns the gene IDH1 and acute myeloid leukemia.